Strong market performance sees additional fundraise for 4d
27th June 2014
Zeus Capital has acted as adviser and broker to 4d pharma on its £21.5 million institutional fund raise.
The Manchester-based company successfully floated on AIM in February 2014 and raised £16.5million. Since its stock market listing the shares have performed well and the company had a market capitalisation of £65m prior to the placing.
4d pharma has focused its interests in the microbiome field and the use of bacteria as live biotherapeutics. The novel field of live biotherapeutics is rapidly growing and developing in both research and interest from pharmaceutical companies and has the potential to fundamentally change the traditional approach of the pharmaceutical industry.
This field, which is a new class of therapeutics, could deliver a significant step in the healthcare market, providing the opportunity to develop medicines that show a greatly improved safety profile, greater efficacy and the possibility of targeting multiple pathways in a single disease.